Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Status
Conditions
Details and patient eligibility
About
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -
Exclusion Criteria:Unable to provide informed consent
Trial contacts and locations
Loading...
Central trial contact
Claire Shovlin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal